Neuropathic pain - brighter future for pipeline drugs with market to double in value to $5.2 billion
The neuropathic pain market is forecast to more than double in value from 2008 to total $5.2 billion by 2018 across the seven major markets - the USA, Japan, and the five leading European Union (France, Germany, Italy, Spain and the UK), according to a new report from Datamonitor. Although the USA will provide the greatest increase in value over this period, Japan and the five EU markets will post double-digit compound annual growth rates.
Highlights of this report show that:
' Eli Lilly/Boehringer Ingelheim's Cymbalta (duloxetine) will continue to struggle to make inroads in this market. Despite publication of favorable meta-analysis data in February 2009 and the possibility of a chronic pain label, Datamonitor has substantially downgraded its neuropathic pain forecast for Cymbalta.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze